On the heels of Amgen Inc. and Allergan PLC launching the first two oncology biosimilars in the US, the US Food and Drug Administration approved a pair of new biosimilars just days later: Pfizer Inc.'s Ruxience (rituximab-pvvr) and Samsung Bioepis Co. Ltd.'s Hadlima (adalimumab-bwwd).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?